# DrugAgent: Explainable Drug Repurposing Agent with Large Language Model-based Reasoning

**Authors:** Yoshitaka Inoue, Tianci Song, Tianfan Fu  
**arXiv:** [2408.13378](https://arxiv.org/abs/2408.13378)  
**Date:** 2024-08-23  
**Summary page:** https://www.summarizepaper.com/en/paper/2408.13378v3/

## Key points

- Drug repurposing is a promising strategy for accelerating drug development by identifying new therapeutic potentials of existing drugs.
- A novel multi-agent framework integrates machine learning techniques and knowledge integration to enhance the drug repurposing process.
- The framework consists of three specialized agents: AI Agent, Knowledge Graph Agent, and Search Agent.
- The collaborative approach allows for flexible adjustment of prediction methods, enhancing overall accuracy.
- Limitations include reliance on human expertise for initial setup and lack of autonomous knowledge updating mechanisms.
- Future research directions include integrating autonomous knowledge updating mechanisms and expanding applicability to a broader range of pharmaceutical tasks.
- Automating preprocessing of complex data types such as scRNA-seq data through optimization frameworks is crucial for improving efficiency in drug repurposing efforts.

## Summary

Drug repurposing is a promising strategy for accelerating drug development by identifying new therapeutic potentials of existing drugs. In this paper, we introduce a novel multi-agent framework designed to enhance the drug repurposing process through the integration of state-of-the-art machine learning techniques and knowledge integration. The framework consists of three specialized agents: an AI Agent that develops robust drug-target interaction (DTI) models using the DeepPurpose package, a Knowledge Graph Agent that synthesizes information on DTIs from various databases such as DGIdb, DrugBank, CTD, and STITCH, and a Search Agent that interacts with biomedical literature for data labeling and validation. By leveraging diverse data sources and analytical methods, our multi-agent system offers more accurate predictions by combining each agent's specialized capabilities to evaluate complex DTIs comprehensively. The collaborative approach allows for flexible adjustment of different prediction methods, enhancing overall accuracy. However, there are limitations to consider when using this multi-agent system. One limitation is the reliance on human expertise for initial setup. Additionally, there is currently a lack of autonomous knowledge updating mechanisms in place to keep pace with evolving pharmacological research. To address these limitations and improve the system's performance in predicting drug efficacy and handling complex drug combinations, future research directions include integrating autonomous knowledge updating mechanisms into the system and expanding its applicability to a broader range of pharmaceutical tasks by incorporating existing models like drGAT for Drug Response Prediction. Another important aspect to consider is automating the preprocessing of complex data types such as scRNA-seq data through optimization frameworks. This will be essential for improving efficiency and accuracy in drug repurposing efforts. Overall, our study demonstrates the potential of multi-agent systems in driving innovation in drug repurposing by leveraging AI technologies and collaborative approaches. By addressing current limitations and focusing on future enhancements, we aim to contribute to advancing computational drug discovery processes towards more efficient and cost-effective outcomes.